相关实验视频

Updated: Jul 10, 2025

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Published on: April 7, 2016

一种新的组合疗法Tβ4/VIP可以保护人类角膜上皮细胞免受高血糖引起的变化

Abdul Shukkur Ebrahim¹, Thomas W Carion¹, Thanzeela Ebrahim¹

¹Department of Ophthalmology, Visual & Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA.

|November 24, 2023

概括

一种新型的疗法,结合了蒂莫β-4 (Tβ4) 和血管活性肠 (VIP),显示出治疗糖尿病角膜损伤的前景. 这种Tβ4/VIP治疗改善了暴露于高葡萄糖的人类角膜细胞的屏障功能和伤口愈合.

科学领域:

眼科医生眼科眼科
内分泌学在内分泌学.
再生医学是一种再生医学.

背景情况:

糖尿病视网膜病变很常见,但角膜并发症,如伤口愈合受损,会显著影响成人糖尿病患者的视力.
糖尿病引起的角膜损伤的有效治疗方法有限,需要新的治疗策略.

研究的目的:

为了研究一种新组合疗法,即提莫辛β-4 (Tβ4) 和血管活性肠 (VIP),用于高葡萄糖诱导的角膜上皮损伤.
评估Tβ4/VIP对角膜上皮质屏障功能和高血糖条件下的伤口愈合的保护作用.

主要方法:

人类角膜上皮细胞在正常 (5 mM) 或高 (25 mM) 葡萄糖条件下培养.
电池基板阻抗传感 (ECIS) 监测了屏障完整性 (电阻,阻抗,电容) 和用于伤口愈合的细胞迁移.
分析了紧结蛋白 (ZO-1,ZO-2,ocludin,claudin-1) 的表达.

主要成果:

高血糖显著损害了角膜上皮质屏障的完整性和伤口愈合.
在高葡萄糖条件下,Tβ4/VIP治疗协同改善了屏障功能和加速细胞迁移.
Tβ4/VIP治疗维持了紧结蛋白水平,抵消了高葡萄糖诱导的下调.

结论:

Tβ4/VIP合疗法有效地保护角膜上皮细胞免受高血糖引起的损伤.
这种协同疗法在糖尿病患者治疗角膜并发症方面具有显著的潜力.
进一步的翻译研究是有必要的,以探索Tβ4/VIP作为糖尿病眼病的治疗选择.

关键词:

这就是T4β4β.一个VIP的VIP的VIP的屏障的完整性屏障的完整性糖尿病糖尿病患者糖尿病患者人类角膜上皮细胞紧密的连接蛋白质紧密的连接蛋白质.

更多相关视频

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Published on: January 10, 2025

Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals

Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals

Published on: September 20, 2021

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...